Haloperidol

Introduction Overview

Generic Name

haloperidol

Brand Name

Haldol

Dosage Form

Oral tablet, Oral liquid, Injectable formulations including intramuscular and decanoate depot formulations

Drug Class

Miscellaneous antipsychotic agents

Pharmacokinetics

Haldol (haloperidol) exhibits complex pharmacokinetic properties typical of first-generation antipsychotics.

Absorption:
Haloperidol is rapidly and well absorbed following oral administration, with bioavailability ranging approximately from 60% to 70%, although first-pass metabolism in the liver can reduce systemic availability. Peak plasma concentrations are generally reached within 2 to 6 hours post-dose. The absorption can be influenced by gastrointestinal motility and food intake, although clinically significant food effects are minimal. Oral liquid and tablet formulations offer flexibility in dosing and patient compliance.

Distribution:
Haloperidol is extensively distributed throughout body tissues, crossing the blood-brain barrier efficiently, which is essential for its antipsychotic action. The drug is highly lipophilic, resulting in a large volume of distribution (approximately 20 L/kg). It is approximately 90% bound to plasma proteins, mainly albumin. The drug also concentrates in tissues such as the brain, lungs, and liver. The high brain penetration correlates with its receptor occupancy and clinical efficacy.

Metabolism:
Haloperidol undergoes extensive hepatic metabolism primarily by the cytochrome P450 system, particularly CYP3A4 and CYP2D6 isoenzymes. Major metabolic pathways include reduction, hydroxylation, and glucuronidation. The formation of active metabolites such as reduced haloperidol contributes to pharmacodynamic effects. Hepatic impairment can alter metabolism, necessitating cautious dosing and monitoring.

Elimination:
The elimination half-life of haloperidol averages between 14 to 26 hours but can vary widely with factors such as age and metabolic capacity. The drug and its metabolites are primarily excreted via the urine (approx. 40-60%) and feces. The decanoate injectable form offers a prolonged elimination phase suitable for long-acting maintenance therapy. Renal clearance is limited, but renal impairment may influence metabolite accumulation. Overall, steady-state plasma levels reflect the balance between dosing regimen and elimination kinetics.

Dosage Forms

Available Dosage Forms:
- Oral tablets: typically available in strengths ranging from 0.5 mg, 1 mg, 2 mg, 5 mg, to 10 mg.
- Oral liquid: available as a concentrate, allowing dosing flexibility; commonly supplied in strengths such as 2 mg/mL.
- Injectable formulations: include intramuscular injections for rapid control of agitation and psychosis.
- Haldol Decanoate: a long-acting injectable depot formulation administered intramuscularly every 4 weeks.

Dosages for Adults and Adolescents:
- For schizophrenia and psychotic disorders, initial oral dosing usually starts at 0.5 to 2 mg two to three times daily.
- Dosage adjustments are guided by patient response, with typical maintenance doses ranging from 3 to 15 mg daily.
- For Tourette’s syndrome, lower doses are recommended, tailored to symptom control and tolerability.
- Injectable doses vary depending on formulation and indication; acute agitation often requires IM dosing 2 to 5 mg every 4 to 8 hours as needed.
- The decanoate depot initiation requires overlap with oral therapy until therapeutic plasma levels are achieved, with typical doses between 50 to 200 mg IM every 4 weeks.

Specific Patient Populations:
- Elderly patients may require lower doses due to increased sensitivity and decreased clearance.
- Patients with hepatic impairment should be closely monitored due to altered metabolism.
- Caution in patients with cardiovascular disease and electrolyte imbalances due to QT prolongation risk.
- Pediatric use is limited and should be strictly under specialist supervision, with doses adjusted according to weight and clinical status.

Clinical guidelines recommend individualized therapy based on clinical response and side effect profile, and slow titration is advised to minimize adverse effects.

Mechanism Of Action

Haloperidol exerts its pharmacological effects primarily through potent antagonism of dopamine D2 receptors in the central nervous system. By binding competitively to these receptors, particularly in the mesolimbic and mesocortical pathways, haloperidol reduces dopaminergic neurotransmission, which is hyperactive in disorders such as schizophrenia and Tourette’s syndrome. This dopamine blockade accounts for its antipsychotic efficacy.

At the cellular level, haloperidol’s antagonism of postsynaptic dopamine receptors leads to decreased intracellular cyclic AMP levels, modulation of signal transduction pathways, and ultimately altered neuronal excitability and neurotransmitter release. It also affects other receptor systems to a lesser extent, including alpha-1 adrenergic, sigma, and serotonin receptors, which may contribute to both therapeutic effects and side effects.

Biochemical interactions with D2 receptors not only alleviate positive symptoms of psychosis but can also induce extrapyramidal motor side effects due to dopamine blockade in the nigrostriatal pathway. Extensive clinical data confirm that haloperidol’s high affinity and relatively slow dissociation from D2 receptors underpin its robust clinical efficacy and risk profile.

Comparatively, haloperidol differs from atypical antipsychotics, which tend to have a broader receptor binding profile with less D2 receptor affinity and additional serotonin receptor antagonism, leading to different efficacy and side effect spectra. Clinical studies support haloperidol's utility in acute psychosis, agitation, and motor tic control, while emphasizing careful monitoring for movement disorders and cardiac effects.

Pharmacological Actions

Potent dopamine D2 receptor antagonist leading to reduced dopaminergic neurotransmission in the brain.
Antipsychotic effect primarily in treatment of schizophrenia and psychotic disorders.
Suppression of motor and vocal tics in Tourette's syndrome.
Exerts sedative effects by central nervous system depression.
Blocks alpha-1 adrenergic receptors causing hypotensive effects in some patients.
Minimal antihistaminic and anticholinergic activity compared to other antipsychotics.
Modulates neurotransmitter systems including serotonin and sigma receptors to a lesser extent.
Induces extrapyramidal side effects due to dopamine blockade in nigrostriatal pathways.
Prolongs QT interval occasionally through effects on cardiac potassium channels.
Exhibits antiemetic properties via central dopamine antagonism.
Long-acting forms (decanoate) provide sustained release for maintenance therapy.
Crosses the blood-brain barrier effectively, achieving significant central receptor occupancy.

Therapeutic Or Clinical Uses

Treatment of schizophrenia and other psychotic disorders.
Management of acute psychotic episodes and agitation in psychiatric emergencies.
Control of motor and vocal tics associated with Tourette's syndrome.
Adjunctive therapy in mania and bipolar disorder (off-label or specific protocols).
Prevention and treatment of nausea and vomiting in select clinical settings (off-label).
Use in intensive care units for agitation and delirium management.
Treatment of severe behavioral disturbances in dementia (though not FDA approved for dementia-related psychosis).
Short-term sedation of severely agitated or delirious patients.
Adjunctive treatment in refractory schizophrenia cases.
Potential use in Huntington’s disease chorea and other hyperkinetic movement disorders (off-label).

Side Or Adverse Effects

Extrapyramidal symptoms including dystonia, akathisia, parkinsonism, and tardive dyskinesia.
Sedation and drowsiness impairing cognitive and motor functions.
Dizziness and orthostatic hypotension leading to fall risk.
Prolongation of the QT interval and associated risk of serious cardiac arrhythmias.
Neuroleptic malignant syndrome characterized by muscle rigidity, fever, autonomic instability.
Elevated prolactin levels causing galactorrhea, menstrual irregularities, and gynecomastia.
Weight gain and metabolic alterations including glucose intolerance.
Anticholinergic effects including dry mouth and blurred vision (less common than other antipsychotics).
Allergic reactions including rash, pruritus, and angioedema.
Nausea, vomiting, and gastrointestinal disturbances.
Seizure risk increase in predisposed patients.
Potential for leukopenia, neutropenia, and agranulocytosis.
Withdrawal symptoms including nausea, vomiting, and insomnia upon abrupt discontinuation.
Elevated risk of death in elderly patients with dementia-related psychosis.
Breast enlargement and irregular menstrual periods.

Precautions

Use with caution in elderly patients, particularly with dementia-related psychosis due to increased mortality risk.
Monitor for extrapyramidal symptoms and tardive dyskinesia, especially with long-term use.
Assess cardiac status prior to and during treatment due to risk of QT prolongation.
Avoid use in patients with Parkinson's disease or severe CNS depression.
Regular monitoring of blood cell counts to detect potential leukopenia or agranulocytosis.
Caution during pregnancy and lactation; potential risk of neonatal complications.
Avoid sudden discontinuation to prevent withdrawal symptoms and relapse of psychosis.
Monitor electrolyte levels, especially potassium and magnesium, in patients at risk.
Use cautiously in patients with seizure disorders, as haloperidol may lower the seizure threshold.
Avoid concomitant use with other central nervous system depressants without medical supervision.
Assess for potential drug interactions before initiating therapy.
Gradual dose adjustments recommended to minimize adverse effects.
Monitoring for metabolic side effects including glucose and lipid abnormalities.
Use in hepatic impairment requires cautious dosing and monitoring.
Educate patients regarding risks of dizziness and impaired motor skills to prevent falls.

Warnings

Not approved for treatment of dementia-related psychosis in older adults; use is associated with increased risk of death.
High doses or long-term use associated with risk of irreversible tardive dyskinesia.
Risk of neuroleptic malignant syndrome, a potentially fatal condition requiring immediate medical intervention.
May cause serious cardiac arrhythmias including torsades de pointes due to QT prolongation.
Potential for severe leukopenia, neutropenia, or agranulocytosis requiring prompt assessment.
Use during pregnancy may lead to neonatal withdrawal symptoms or extrapyramidal symptoms.
Avoid abrupt discontinuation to prevent withdrawal and exacerbation of underlying psychiatric condition.
May impair ability to perform hazardous tasks such as driving or operating machinery.
Concomitant use with other QT-prolonging drugs increases risk of life-threatening arrhythmias.
Alcohol use may exacerbate sedative effects and hypotension.
Caution in patients with history of cardiovascular disease or electrolyte imbalances.
Risk of orthostatic hypotension especially during initial dose escalation.
Potential for hyperprolactinemia and associated endocrine effects.
Patients should be monitored for mood and behavioral changes, including suicidality.
Use with caution in individuals with seizure disorders.

Contraindication

Known hypersensitivity to haloperidol or any component of the formulation.
Patients with Parkinson's disease due to dopamine antagonism exacerbating symptoms.
Severe central nervous system depression or comatose states.
Certain conditions causing QT prolongation or known history of long QT syndrome.
Use concomitantly with medications known to induce torsades de pointes without extreme caution.
Patients with history of neuroleptic malignant syndrome related to previous antipsychotic therapy.
Severe cardiovascular disease with unstable arrhythmias or recent myocardial infarction.
Known hypersensitivity to excipients in specific formulations (e.g., preservatives in injectables).
Avoid use in patients who have demonstrable conditions incompatible with dopamine antagonism.
Patients with severe electrolyte abnormalities prior to correction.
Pediatric patients except in specific indications under specialist supervision.
Hypersensitivity to peanuts or soy in formulations containing such excipients.
Use during the third trimester of pregnancy except when benefits outweigh risks.
Patients with history of agranulocytosis from previous antipsychotic treatment.
Severe hepatic impairment without the ability to monitor and adjust dosing.

Drug Interactions

Concomitant use with other QT prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics) increases risk of torsades de pointes.
Increased sedation and respiratory depression when combined with CNS depressants such as benzodiazepines, opioids, or alcohol.
Metabolism can be altered by CYP3A4 and CYP2D6 inhibitors or inducers (e.g., rifampin reduces haloperidol levels; fluoxetine may increase haloperidol levels).
Possible increased risk of extrapyramidal symptoms when used with lithium.
Warfarin and other anticoagulants affected by possible alterations in metabolism or platelet function.
Antihypertensives may have additive hypotensive effects when combined with haloperidol.
Interactions with anticonvulsants, especially those that induce CYP enzymes, affecting haloperidol levels.
Combining with drugs that lower seizure threshold may exacerbate seizure risk.
Pharmacodynamic interaction with anticholinergic drugs may alter side effect profile.
Co-administration with dopamine agonists, such as levodopa, may reduce efficacy.
Potential interaction with serotoninergic drugs possibly increasing risk of serotonin syndrome.
Additive QT prolongation risk with other psychotropic medications like tricyclic antidepressants or SSRIs.
Caution with drugs affecting electrolyte balance as hypokalemia or hypomagnesemia enhance arrhythmia risk.
Possible interference with laboratory tests, necessitating awareness during monitoring.
Herbal supplements such as St. John's Wort may decrease haloperidol plasma concentrations via CYP induction.

Preparations Of The Drug

Oral tablets available in multiple strengths including 0.5 mg, 1 mg, 2 mg, 5 mg, and 10 mg.
Oral solution formulations allowing flexible dosing in mg/mL concentration.
Intramuscular injection formulations for acute management of agitation and psychosis.
Haldol Decanoate, a long-acting injectable depot formulation administered every 4 weeks for maintenance therapy.
Preservative-containing and preservative-free injectable preparations for parenteral use.
Liquid concentrate formulations requiring precise measuring devices or syringes.
Combination packaging including blister packs and bottles for outpatient use.
Commercially available generics with formulation consistency and fixed dosing strengths.
Sterile injectable ampules for hospital and emergency use.
Specialized compounding options for patients with swallowing difficulties or dosing adjustments.
Supply packaging with detailed patient information leaflets and dosing guidance.
Intravenous formulations exist but are less commonly used due to safety concerns.
Various formulation excipients designed to enhance stability and patient tolerability.
Storage recommendations include protection from moisture, heat, and light; liquid formulations should not be frozen.
All preparations require storage at room temperature unless otherwise specified by manufacturer.